Ethics and Policy Core

道德和政策核心

基本信息

  • 批准号:
    10274455
  • 负责人:
  • 金额:
    $ 7.55万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-09-30 至 2026-05-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY The goal of the Penn Artificial Intelligence and Technology (PennAITech) Collaboratory is to identify, develop, evaluate, commercialize, and disseminate innovative technology for monitoring aging adults and persons with Alzheimer's disease and Alzheimer’s disease related dementias (AD/ADRD) in their home environment and the artificial intelligence (AI) methods and software for analyzing data generated by those technologies for improving clinical care. This will help aging Americans live safe, social, and engaged lives. To date, the science of AI and monitoring technologies has often outpaced existing ethical and policy frameworks, and the unique ethical and policy implications for older adults, including older adults experiencing cognitive decline/impairment and their care partners, have largely been overlooked. Therefore, there is a critical need for ethics and policy scholarship—in conversation both with the science of AI and monitoring technology and also with the science of aging and AD/ADRD—throughout the research phase, as well as during its translation into viable interventions. To address this need, the Ethics and Policy Core will work in close collaboration with the other PennAITech Collaboratory Cores with a focus on four key issues: promoting the autonomy of older adults by balancing considerations of usefulness and intrusiveness; protecting older adults in light of vulnerability due to cognitive and functional decline; mitigating bias and addressing health disparities, such as racial disparities and urban-rural disparities; and safeguarding the data privacy of older adults. In order to accomplish this, the Ethics and Policy Core has three aims: (1) to provide guidance and training to PennAITech Collaboratory-funded pilot project leaders, trainees, and industry leaders on ethical and policy issues encountered in researching and developing AI methods and technologies for healthy aging; (2) to examine the ethical and policy barriers to using AI methods and technologies for healthy aging from the perspective of diverse stakeholders, including healthy older adults, adults with AD/ADRD, and care partners; and (3) to serve as a national resource for the research community by disseminating guidelines and best practices related to developing AI methods and technologies for healthy aging and translating them into care with a focus on healthy older adults, adults with AD/ADRD, and care partners. This innovative and impactful Core will be led by Emily A. Largent, JD, PhD, RN, an authority on bioethical and policy issues in research and care involving older adults and persons living with AD/ADRD, and it will engage a multidisciplinary team of experts to reach its overarching goal.
项目摘要 宾夕法尼亚人工智能和技术(Pennaitech)合作的目标是识别,开发,开发, 评估,商业化和传播创新技术,以监测老龄化的成年人和患者 阿尔茨海默氏病和阿尔茨海默氏病与痴呆症相关的痴呆症(AD/ADRD) 人工智能(AI)方法和软件用于分析这些技术生成的数据 改善临床护理。这将有助于衰老的美国人生活安全,社交和敬业的生活。迄今为止, AI和监测技术的科学经常超过现有的道德和政策框架,以及 对老年人的独特道德和政策影响,包括经历认知的老年人 衰落/障碍及其护理伙伴在很大程度上被忽略了。因此,有急需 对于道德和政策科学 - 在与AI的科学和监测技术的对话中 还通过衰老和广告/ADR的科学 - 通过研究阶段以及翻译期间 进入可行的干预措施。为了满足这一需求,道德和政策核心将与 其他Pennaitech合作核心,重点是四个关键问题:促进年长的自主权 通过平衡有用性和侵入性考虑的成年人;根据 由于认知和功能下降而引起的脆弱性;减轻偏见并解决健康分配,例如 种族差异和城乡差异;并保护老年人的数据隐私。为了 这样做,道德和政策核心具有三个目标:(1)提供指导和培训 Pennaitech合作资助的试点项目领导者,培训和行业领导者的道德和政策领导者 在研究和开发健康衰老的AI方法和技术方面遇到的问题; (2)至 检查使用AI方法和技术从中衰老的道德和政策障碍 潜水员利益相关者的观点,包括健康的老年人,有广告/ADRD的成年人和护理伙伴; (3)通过传播准则和最佳方式作为研究界的国家资源 与开发健康衰老的AI方法和技术有关的实践,并将其转化为护理 专注于健康的老年人,患有广告/ADRD的成年人和护理伙伴。这种创新和有影响力的 核心将由Emily A. Largent,JD,PhD,RN领导,RN,研究的授权 护理涉及老年人和与AD/ADRD的人一起,它将与一个多学科团队组成 专家实现其总体目标。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Emily Largent其他文献

Emily Largent的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Emily Largent', 18)}}的其他基金

Adapting supported decision making to promote wellbeing and improve health outcomes for persons living with Alzheimer's disease and Alzheimer's disease related dementias
调整支持性决策,以促进阿尔茨海默病和阿尔茨海默病相关痴呆症患者的福祉并改善其健康结果
  • 批准号:
    10437135
  • 财政年份:
    2022
  • 资助金额:
    $ 7.55万
  • 项目类别:
Adapting supported decision making to promote wellbeing and improve health outcomes for persons living with Alzheimer's disease and Alzheimer's disease related dementias
调整支持性决策,以促进阿尔茨海默病和阿尔茨海默病相关痴呆症患者的福祉并改善其健康结果
  • 批准号:
    10624351
  • 财政年份:
    2022
  • 资助金额:
    $ 7.55万
  • 项目类别:
Ethics and Policy Core
道德和政策核心
  • 批准号:
    10491803
  • 财政年份:
    2021
  • 资助金额:
    $ 7.55万
  • 项目类别:
Ethics and Policy Core
道德和政策核心
  • 批准号:
    10685547
  • 财政年份:
    2021
  • 资助金额:
    $ 7.55万
  • 项目类别:
UNDERSTANDING HOW THE STUDY PARTNER REQUIREMENT IMPACTS THE DISCOVERY AND TRANSLATION OF PRECLINICAL ALZHEIMERS DISEASE
了解研究合作伙伴要求如何影响临床前阿尔茨海默病的发现和转化
  • 批准号:
    10683182
  • 财政年份:
    2019
  • 资助金额:
    $ 7.55万
  • 项目类别:
UNDERSTANDING HOW THE STUDY PARTNER REQUIREMENT IMPACTS THE DISCOVERY AND TRANSLATION OF PRECLINICAL ALZHEIMERS DISEASE
了解研究合作伙伴要求如何影响临床前阿尔茨海默病的发现和转化
  • 批准号:
    9980755
  • 财政年份:
    2019
  • 资助金额:
    $ 7.55万
  • 项目类别:
UNDERSTANDING HOW THE STUDY PARTNER REQUIREMENT IMPACTS THE DISCOVERY AND TRANSLATION OF PRECLINICAL ALZHEIMERS DISEASE
了解研究合作伙伴要求如何影响临床前阿尔茨海默病的发现和转化
  • 批准号:
    10403518
  • 财政年份:
    2019
  • 资助金额:
    $ 7.55万
  • 项目类别:
UNDERSTANDING HOW THE STUDY PARTNER REQUIREMENT IMPACTS THE DISCOVERY AND TRANSLATION OF PRECLINICAL ALZHEIMERS DISEASE
了解研究合作伙伴要求如何影响临床前阿尔茨海默病的发现和转化
  • 批准号:
    9806426
  • 财政年份:
    2019
  • 资助金额:
    $ 7.55万
  • 项目类别:

相似国自然基金

时空序列驱动的神经形态视觉目标识别算法研究
  • 批准号:
    61906126
  • 批准年份:
    2019
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目
本体驱动的地址数据空间语义建模与地址匹配方法
  • 批准号:
    41901325
  • 批准年份:
    2019
  • 资助金额:
    22.0 万元
  • 项目类别:
    青年科学基金项目
大容量固态硬盘地址映射表优化设计与访存优化研究
  • 批准号:
    61802133
  • 批准年份:
    2018
  • 资助金额:
    23.0 万元
  • 项目类别:
    青年科学基金项目
IP地址驱动的多径路由及流量传输控制研究
  • 批准号:
    61872252
  • 批准年份:
    2018
  • 资助金额:
    64.0 万元
  • 项目类别:
    面上项目
针对内存攻击对象的内存安全防御技术研究
  • 批准号:
    61802432
  • 批准年份:
    2018
  • 资助金额:
    25.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

REVAMP-PH: REpurposing Valsartan May Protect against Pulmonary Hypertension
REVAMP-PH:重新利用缬沙坦可以预防肺动脉高压
  • 批准号:
    10642368
  • 财政年份:
    2023
  • 资助金额:
    $ 7.55万
  • 项目类别:
Perspectives of Correctional Officers about Older Adults in Prison: A Grounded Theory Study
惩教人员对监狱中老年人的看法:扎根理论研究
  • 批准号:
    10749275
  • 财政年份:
    2023
  • 资助金额:
    $ 7.55万
  • 项目类别:
Pterygopalatine Fossa (PPF) Block as an Opioid Sparing Treatment for AcuteHeadache in Aneurysmal Subarachnold Hemorrhage
翼腭窝 (PPF) 阻滞作为阿片类药物节省治疗动脉瘤性蛛网膜下腔出血的急性头痛
  • 批准号:
    10584712
  • 财政年份:
    2023
  • 资助金额:
    $ 7.55万
  • 项目类别:
Understanding the immune response changes to clinical interventions for Epstein-Barr virus infection prior to lymphoma development in children after organ transplants (UNEARTH)
了解器官移植后儿童淋巴瘤发展之前针对 Epstein-Barr 病毒感染的临床干预的免疫反应变化(UNEARTH)
  • 批准号:
    10755205
  • 财政年份:
    2023
  • 资助金额:
    $ 7.55万
  • 项目类别:
3D force sensing insoles for wearable, AI empowered, high-fidelity gait monitoring
3D 力传感鞋垫,用于可穿戴、人工智能支持的高保真步态监控
  • 批准号:
    10688715
  • 财政年份:
    2023
  • 资助金额:
    $ 7.55万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了